Neuraly, Inc.

This study tested a new medicine called DD01 in 67 overweight or obese adults with a type of fatty liver disease (MASLD or MASH). The goal was to see if DD01 could safely reduce liver fat over 48 weeks compared to a placebo. Participants were randomly assigned to receive either D…